Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 262 clinical trials
Intratumoral Tilsotolimod a TLR-9 Agonist Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

Open label, phase Ib study of intratumoral tilsotolimod in combination with intratumoral ipilimumab and intravenous nivolumab. The trial will be divided into two parts: PART A: the first part will assess the safety of two regimen and will recruit patients with all types of injectable solid malignancies PART B: the …

cancer treatment
fluorouracil
blood transfusion
hcg pregnancy test
non-small cell lung cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

This is an open label Phase 1, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic, colon and lung cancers.

solid tumor
cancer treatment
HER2
hair thinning
lung cancer
  • 0 views
  • 05 Aug, 2020
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Eligibility People age 18 and older who have a rare, advanced cancer that has progressed after receiving standard treatment, or for which no effective therapy exists. Design Participants will be screened with medical history and physical exam.

giant cell tumors
cholangiocarcinoma
lepidic predominant adenocarcinoma
serous cystadenocarcinoma
bronchioloalveolar carcinoma
  • 0 views
  • 16 Feb, 2024
  • 1 location
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

This is a Phase 1, multicenter, open-label, multiple-dose, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, and pharmacodynamics of TTX-080 monotherapy in subjects with advanced or metastatic solid tumors known to express HLA-G. This first-in-human (FIH) study has been designed to evaluate the safety, tolerability, and preliminary antitumor …

metastasis
cancer
solid tumour
measurable disease
hla-g
  • 0 views
  • 05 Aug, 2020
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).

  • 0 views
  • 20 Jul, 2022
  • 24 locations
Ketamine or Placebo in Patients With Major Depression and Advanced Cancer

MD is a frequent complication in patients who are diagnosed with advanced cancer.

cancer diagnosis
sleep disorder
fatigue
anhedonia
advanced cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
Microbiome and Rectal Cancer

The purpose of our study is to determine if an association exists between the microbiome of those with rectal adenocarcinoma who are complete pathologic responders and those who have a partial or no response to neoadjuvant therapy.

adenocarcinoma of rectum
adjuvant therapy
neoadjuvant therapy
adenocarcinoma
cancer
  • 0 views
  • 16 Feb, 2024
  • 3 locations
A Clinical Study of Intravenous Administration of RT-01 in Patients With Advanced Solid Tumors

This is an open-label, dose escalation study of the safety and tolerability of oncolytic virus injection(RT-01) when administered via Intravenous injection in patients with advanced solid tumors. The purpose of this study is to assess the safety and tolerability of RT-01 and to determine the recommended phase 2 dose (RP2D) …

  • 0 views
  • 14 Mar, 2022
  • 1 location
NBE-002 in Patients With Advanced Solid Tumors

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.

anthracycline
solid tumour
carcinoma
anthracyclines
cancer
  • 0 views
  • 05 Aug, 2020
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs (KYANITE-1)

The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebulization, delivering the therapy directly through the airways to the lungs …

  • 0 views
  • 12 Dec, 2025